Skip to main content
SpringerLink
Log in

The European Medicines Agency is recommending that becaplermin [Regranex] be contraindicated in patients with any pre-existing cancer,

  • Media release
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. European Medicines Agency.European Medicines Agency recommends contraindication for Regranex in patients with any pre-existing cancer. Media Release: 18 Feb 2010. Available from: URL: http://www.ema.europe.eu

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

The European Medicines Agency is recommending that becaplermin [Regranex] be contraindicated in patients with any pre-existing cancer,. React. Wkly. 1290, 2 (2010). https://doi.org/10.2165/00128415-201012900-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-201012900-00003

Keywords

Search

Navigation